Lifileucel clinical trials
Also written LN-144.
How each study uses lifileucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lifileucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Feb 2024 · AMTAGVI · BLA 125773 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 11
Iovance Biotherapeutics, Inc. (10) · Memorial Sloan Kettering Cancer Center (2) · Vastra Gotaland Region (2) · Shanghai Juncell Therapeutics (2) · Richard Wu (1) · University of Kansas Medical Center (1) · Abramson Cancer Center at Penn Medicine (1) · Karam Khaddour, MD, MS (1)
Often tested with
Tested in the same studies.
Autologous Tumor Infiltrating Lymphocytes LN-145 (12) · Interleukin-2 (2) · Autologous Tumor Infiltrating Lymphocytes LN-145-S1 (2) · Melphalan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Lifileucel is the comparator. A study of two new drugs counts under both.
- 1Anzutresgene autoleucel · Immatics US, Inc. · next primary completion Jan 2028
Reaching primary completion within a year · 4
Studies that test lifileucel.
- Jan 2027A Phase Ib Study of GC101 in NSCLCPhase 1 · Shanghai Juncell Therapeutics
- May 2027A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaPhase 1 · Memorial Sloan Kettering Cancer Center
- Jun 2027A Phase II Study of GC101 in NSCLCPhase 2 · Shanghai Juncell Therapeutics
- Nov 2027A Study of LN-144 in People With Metastatic Melanoma to the BrainPhase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses lifileucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue SarcomaRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT07741877Written as Lifileucel
- Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.RecruitingPhase 3Iovance Biotherapeutics, Inc.NCT05727904Written as Lifileucel plus Pembrolizumab
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05607095Written as Lifileucel (LN-144/LN-145)
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingPhase 1Vastra Gotaland RegionNCT05903937Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase Ib Study of GC101 in NSCLCRecruitingPhase 1Shanghai Juncell TherapeuticsNCT06473961Written as Autologous Tumor Infiltrating Lymphocytes
- A Phase II Study of GC101 in NSCLCRecruitingPhase 2Shanghai Juncell TherapeuticsNCT07560111Written as Autologous Tumor Infiltrating Lymphocytes
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaNot yet recruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT07700121Written as Lifileucel Infusion
- Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerRecruitingPhase 2Iovance Biotherapeutics, Inc.NCT04614103Written as LN-145
- TIL Therapy in cSCC and MCCRecruitingPhase 2Karam Khaddour, MD, MSNCT07288073Written as LN-145
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.RecruitingPhase 2Iovance Biotherapeutics, Inc.NCT06481592Written as Lifileucel
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver CancerRecruitingPhase 1Zhiyong HuangNCT06084299Written as Autologous Tumor Infiltrating Lymphocytes
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced MelanomaActive, not recruitingPhase 2Iovance Biotherapeutics, Inc.NCT07288203Written as Lifileucel
- Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03108495Written as LN-145
- A Study of LN-144 in People With Metastatic Melanoma to the BrainActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05640193Written as Lifileucel (LN-144)
- Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedPhase 2Iovance Biotherapeutics, Inc.NCT03645928Written as Lifileucel
- Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic MelanomaCompletedPhase 2University of Kansas Medical CenterNCT06151847Written as Lifileucel
- Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaCompletedPhase 2Iovance Biotherapeutics, Inc.NCT02360579Written as Lifileucel
- Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingPhase 1Richard WuNCT05176470Written as Lifileucel
- Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver MetastasesCompletedPhase 1Vastra Gotaland RegionNCT04812470Written as Autologous Tumor Infiltrating Lymphocytes
- Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsTerminatedPhase 1Gregory DanielsNCT03991741Written as Autologous Tumor Infiltrating Lymphocytes
See all 23 studies that test lifileucel →
Given beside what is tested · 1 — lifileucel is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with lifileucel
Codes
What other systems call lifileucel · ClinicalTrials.gg INT017737
- UNII (FDA) R0835E18NHLIFILEUCELOne source FDA
- NCI Thesaurus C120552LifileucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R0835E18NH | LIFILEUCEL | One source FDA |
| NCI Thesaurus | C120552 | Lifileucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.